Biomedical Engineering Reference
In-Depth Information
146. Vassilopoulos G, Wang PR, Russell DW (2003) Transplanted bone marrow regenerates
liver by cell fusion. Nature 422:901-904
147. Willenbring H, Bailey AS, Foster M, Akkari Y, Dorrell C, Olson S, Finegold M, Fleming
WH, Grompe M (2004) Myelomonocytic cells are sufficient for therapeutic cell fusion in
liver. Nat Med 10:744-748
148. Sinn
PL,
Sauter
SL,
McCray
PB
Jr
(2005)
Gene
therapy
progress
and
prospects:
development
of
improved
lentiviral
and
retroviral
vectors—design,
biosafety,
and
production. Gene Ther 12:1089-1098
149. Bey H, Abina S, von Kalle C et al (2003) A serious adverse event after successful gene
therapy for X-linked severe combined immunodeficiency. N Engl J Med 348:255-256
150. Rettinger SD, Ponder KP, Saylors RL, Kennedy SC, Hafenrichter DG, Flye MW (1993) In
vivo hepatocyte transduction with retrovirus during in-flow occlusion. J Surg Res 54:418-425
151. Branchereau S, Calise D, Ferry N (1994) Factors influencing retroviral-mediated gene
transfer into hepatocytes in vivo. Hum Gene Ther 5:803-808
152. Amado RG, Chen IS (1999) Lentiviral vectors—the promise of gene therapy within reach.
Science 285:674-676
153. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM (1997) Sustained expression of genes
delivered directly into liver and muscle by lentiviral vectors. Nat Genet 17:314-317
154. Ghosh SS, Gopinath P, Ramesh A (2006) Adenoviral vectors: a promising tool for gene
therapy. Appl Biochem Biotechnol 133:9-29
155. The Journal of Gene Medicine. The Journal of Gene Medicine Clinical Trial site. Available
from URL:
http://www.wiley.co.uk/wileychi/genmed/clinical/
.
22 Dec 2008
156. Jager L, Ehrhardt A (2007) Emerging adenoviral vectors for stable correction of genetic
disorders. Curr Gene Ther 7:272-283
157. Peng Z (2005) Current status of gendicine in China: recombinant human Ad-p53 agent for
treatment of cancers. Hum Gene Ther 16:1016-1027
158. Marshall E (1999) Gene therapy death prompts review of adenovirus vector. Science
286:2244-2245
159. Grieger JC, Samulski RJ (2005) Adeno-associated virus as a gene therapy vector: vector
development, production and clinical applications. Adv Biochem Eng Biotechnol 99:119-145
160. Wu Z, Asokan A, Samulski RJ (2006) Adeno-associated virus serotypes: vector toolkit for
human gene therapy. Mol Ther 14:316-327
161. Samulski RJ, Zhu X, Xiao X et al (1991) Targeted integration of adeno-associated virus
(AAV) into human chromosome 19. EMBO J 10:3941-3950
162. Young SM Jr, McCarty DM, Degtyareva N, Samulski RJ (2000) Roles of adeno-associated
virus Rep protein and human chromosome 19 in site-specific recombination. J Virol
74:3953-3966
163. Howden SE, Voullaire L, Vadolas J (2007) The transient expression of mRNA coding for
Rep protein from AAV facilitates targeted plasmid integration. J Gene Med 10:42-50
164. Coura Rdos S, Nardi NB (2007) The state of the art of adeno-associated virus-based vectors
in gene therapy. Virol J 4:99
165. Merle U, Encke J, Tuma S, Volkmann M, Naldini L, Stremmel W (2006) Lentiviral gene
transfer ameliorates disease progression in Long-Evans cinnamon rats: an animal model for
Wilson disease. Scand J Gastroenterol 41:974-982
166. Ghosh A, Allamarvdasht M, Pan CJ et al (2006) Long-term correction of murine glycogen
storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer.
Gene Ther 13:321-329
167. Yiu WH, Pan CJ, Allamarvdasht M, Kim SY, Chou JY (2007) Glucose-6-phosphate
transporter gene therapy corrects metabolic and myeloid abnormalities in glycogen storage
disease type Ib mice. Gene Ther 14:219-226
168. Kobayashi H, Carbonaro D, Pepper K et al (2005) Neonatal gene therapy of MPS I mice by
intravenous injection of a lentiviral vector. Mol Ther 11:776-789
169. Di Natale P, Di Domenico C, Gargiulo N et al (2005) Treatment of the mouse model of
mucopolysaccharidosis type IIIB with lentiviral-NAGLU vector. Biochem J 388:639-646
